INO Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of -5.39%. Inovio Pharmaceuticals's return on equity of -119.02% beat ANI Pharmaceuticals's return on equity of -4.07%.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 321.15%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $81.88 which suggests that it could grow by 12.84%. Given that Inovio Pharmaceuticals has higher upside potential than ANI Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than ANI Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.401, which suggesting that the stock is 40.133% more volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.834%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than ANI Pharmaceuticals quarterly revenues of $190.6M. Inovio Pharmaceuticals's net income of -$19.4M is lower than ANI Pharmaceuticals's net income of -$10.3M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 2.29x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of -91.76%. Inovio Pharmaceuticals's return on equity of -119.02% beat Novavax's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 321.15%. On the other hand Novavax has an analysts' consensus of $15.57 which suggests that it could grow by 148.35%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Inovio Pharmaceuticals has a beta of 1.401, which suggesting that the stock is 40.133% more volatile than S&P 500. In comparison Novavax has a beta of 3.210, suggesting its more volatile than the S&P 500 by 220.956%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Novavax quarterly revenues of $88.3M. Inovio Pharmaceuticals's net income of -$19.4M is higher than Novavax's net income of -$81M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.44x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of 35.65%. Inovio Pharmaceuticals's return on equity of -119.02% beat Protalix BioTherapeutics's return on equity of 8.75%.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 321.15%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 410.56%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.401, which suggesting that the stock is 40.133% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Inovio Pharmaceuticals's net income of -$19.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 94.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 4.41x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of -309.84%. Inovio Pharmaceuticals's return on equity of -119.02% beat Sangamo Therapeutics's return on equity of -217.48%.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 321.15%. On the other hand Sangamo Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 594.44%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 1.401, which suggesting that the stock is 40.133% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.456, suggesting its more volatile than the S&P 500 by 45.634%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Sangamo Therapeutics quarterly revenues of $7.6M. Inovio Pharmaceuticals's net income of -$19.4M is higher than Sangamo Therapeutics's net income of -$23.4M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 2.52x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.